Since 1984, 447 articles have been published using the acronym "SAD" for seasonal affective disorder in the heading of the publication, and since 1992, 59 articles have used "SAD" in the heading of the publication as an acronym for social anxiety disorder, according to MEDLINE. Using the acronym SAD for social anxiety disorder has been used with more frequency in recent scientific publications-interestingly, mostly in connection with newer antidepressants that have been found to be of therapeutic potential for this indication. To avoid possible confusions in research, the acronym "SOAD" was proposed for social anxiety disorder by Kasper and Winkler In the early 1980s, Rosenthal and colleagues 2 at the National Institute of Mental Health (NIMH) set out to describe a syndrome called SAD, not to be confused with the other, more recent SAD, social anxiety disorder. The original has been known to physicians since ancient times, dating back to Aretaeus the Cappadocian. 34 However, the NIMH researchers for the first time systematically described the clinical symptomatology, compared it with healthy controls, and differentiated SAD from nonseasonal depression. Their work in tandem with emerging technology led to the discovery of the underlying pathophysiology of SAD and treatment approaches. The most important of these approaches were light therapy and pharmacotherapeutic options.
In the early 1980s, Rosenthal and colleagues 2 at the National Institute of Mental Health (NIMH) set out to describe a syndrome called SAD, not to be confused with the other, more recent SAD, social anxiety disorder. The original has been known to physicians since ancient times, dating back to Aretaeus the Cappadocian. 34 However, the NIMH researchers for the first time systematically described the clinical symptomatology, compared it with healthy controls, and differentiated SAD from nonseasonal depression. Their work in tandem with emerging technology led to the discovery of the underlying pathophysiology of SAD and treatment approaches. The most important of these approaches were light therapy and pharmacotherapeutic options.
The articles in this issue summarize the existing literature on epidemiological, diagnostic, and symptomatological characteristics of SAD, and the underlying biology, which further elucidates the understanding of the mechanisms involved in affective disorders.
SAD research indicates that there is a dimension in the general population that spans from healthy individuals over subsyndromal SAD to SAD patients. As Andres Magnusson, MD, PhD, and Timo Partonen, MD, PhD, illustrate, epidemiological research reveals that SAD individuals are often drug-naive and prefer light therapy, if any at all.
Next, Chang-Ho Sohn, MD, and Raymond W. Lam, MD, FRCPC, update one of their previous studies, showing that biological research has elucidated that SAD patients are not fundamentally different in their pathophysiology compared with nonseasonal depression.
Light therapy is among the best-studied nonpharmacologic biological-oriented treatment approaches, and has emerged as the logical treatment for SAD. The analysis of existing data sets by Michael Terman, PhD, and Jiuan Su Terman, PhD, substantiates that for the indication of SAD the effect size of light therapy is comparable with pharmacologic treatments and that ideally treatment should start in the morning hours. However, if this regimen cannot be followed, treatment during the day or in the late afternoon/evening is also acceptable.
Edda Pjrek, MD, and colleagues explain that biological studies accompanying light therapy indicate that neurotransmitter systems involved in psychopharmacologic treatments are also involved in the pathophysiology of light therapy. The serotonin system has been the most extensively studied, and has revealed that after successful treatment with light therapy, values are comparable with healthy controls. Pharmacologic treatment indicates a positive effect for medication affecting the serotonergic as well as the noradrenergic system. However, the largest data set available is for only serotonergic medication, including sertraline and citalopram.
This issue is meant to summarize the set of available clinically relevant aspects of SAD and reinvigorate interest in this field. If these articles spur further research and, in turn, provide improved treatment for SAD patients, we have achieved our goal. D 3 3 In managing insomnia *Next-day residual effects were evaluated in 7 studies involving normal volunteers. In 3 studies in adults (including 1 study in a phase-advance model of transient insomnia) and 1 study in elderly subjects, a small but statistically significant decrease in performance was observed in the Digit Symbol Substitution Test (DSST) when compared with placebo. Studies in nonelderly patients with insomnia did not detect evidence of next-day residual effects using the DSST, the Multiple Sleep Latency Test (MSLT), and patient ratings of alertness.
1 AMBIEN is indicated for the short-term treatment of insomnia. In elderly or debilitated patients, or patients with hepatic dysfunction, treatment should be initiated with a 5-mg dose and patients closely monitored. Due to its rapid onset of action, patients should take AMBIEN right before going to bed and when ready for sleep. Patients should not take AMBIEN unless they are prepared to get a full night's sleep (7 to 8 hours) to avoid residual effects. Until they know how it will affect their physical or mental performance upon awakening, patients should not drive or operate hazardous machinery after taking AMBIEN or any other sleep medication. During short-term treatment with AMBIEN, the most commonly observed adverse effects in controlled clinical trials were drowsiness (2%), dizziness (1 %), and diarrhea (1 %). Because individuals with a history of addiction or substance abuse are at increased risk of habituation and dependence, they should be under careful surveillance when receiving AMBIEN or any other hypnotic. AMBIEN is classified as a Schedule IV controlled substance. Sedative hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. Hypnotics should generally be limited to 7 to 10 days of use, and reevaluation of the patient is recommended if they are taken for more than 2 to 3 weeks. Prescriptions for AMBIEN should not exceed a 1-month supply.
Please see brief summary of prescribing information on back.
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CONTRAINDICATIONS

None known.
WARNINGS Since sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness which should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hypnotic drugs, including Ambien. Because some of the important adverse effects of Ambien appear to be dose related (see Precautions and Dosage and Administration), it is important to use the smallest possible effective dose, especially in the elderly.
A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of sedative/hypnotics. Some of these changes may be characterized by decreased inhibition (eg, aggressiveness and extroversion that seemed out of character), similar to effects produced by alcohol and other CNS depressants, Other reported behavioral changes have included bizarre behavior, agitation, hallucinations, and depersonalization. Amnesia and other neuropsychiatric symptoms may occur unpredictably. In primarily depressed patients, worsening of depression, including suicidal thinking, has been reported in association with the use of sedative/hypnotics.
It can rarely be determined with certainty whether a particular instance of the abnormal behaviors listed above is drug induced, spontaneous in origin, or a result of an underlying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of concern requires careful and immediate evaluation, Following the rapid dose decrease or abrupt discontinuation of sedative/hypnotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs (see Drug Abuse and Dependence), Ambien, like other sedative/hypnotic drugs, has CNS-depressant effects. Due to the rapid onset of action, Ambien should only be ingested immediately prior to going to bed. Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of Ambien. Ambien showed additive effects when combined with alcohol and should not be taken with alcohol. Patients should also be cautioned about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when Ambien is administered with such agents because of the potentially additive effects.
PRECAUTIONS
General
Use in the elderly and/or debilitated patients: Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended Ambien dosage is 5 mg in such patients (see Dosage and Administration) to decrease the possibility of side effects. These patients should be closely monitored. Use in patients with concomitant illness: Clinical experience with Ambien in patients with concomitant systemic illness is limited. Caution is advisable in using Ambien in patients with diseases or conditions that could affect metabolism or hemodynamic responses. Although studies did not reveal respiratory depressant effects at hypnotic doses of Ambien in normals or in patients with mild to moderate chronic obstructive pulmonary disease (COPD), a reduction in the Total Arousal Index together with a reduction in lowest oxygen saturation and increase in the times of oxygen desaturation below 80% and 90% was observed in patients with mild-to-moderate sleep apnea when treated with Ambien (10 mg) when compared to placebo. However, precautions should be observed if Ambien is prescribed to patients with compromised respiratory function, since sedative/hypnotics have the capacity to depress respiratory drive. Post-marketing reports of respiratory insufficiency, most of which involved patients with pre-existing respiratory impairment, have been received. Data in end-stage renal failure patients repeatedly treated with Ambien did not demonstrate drug accumulation or alterations in pharmacokinetic parameters. No dosage adjustment in renally impaired patients is required; however, these patients should be closely monitored (see Pharmacokinetics). A study in subjects with hepatic impairment did reveal prolonged elimination in this group; therefore, treatment should be initiated with 5 mg in patients with hepatic compromise, and they should be closely monitored.
Use in depression:
As with other sedative/hypnotic drugs, Ambien should be administered with caution to patients exhibiting signs or symptoms of depression. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time. Information for patients: Patient information is printed in the complete prescribing information. Laboratory tuts: There are no specific laboratory tests recommended. Drug interactions CNS-activa drugs: Ambien was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs, A study involving haloperidol and zoipidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zoipidem. Imipramine in combination with zoipidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zoipidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance. The lack of a drug interaction following single-dose administration does not predict a lack following chronic administration.
An additive effect on psychomotor performance between alcohol and zoipidem was demonstrated.
A single-dose interaction study with zoipidem 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or pharmacodynamic interactions. When multiple doses of zoipidem and fluoxetine at steady-state concentrations were evaluated in healthy females, the only significant change was a 17% increase in the zoipidem half-life. There was no evidence of an additive effect in psychomotor performance.
Following five consecutive nightly doses of zoipidem 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zoipidem Cmui was significantly higher (43%) and Tma, was significantly decreased (53%). Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zoipidem.
Since the systematic evaluations of Ambien in combination with other CNSactive drugs have been limited, careful consideration should be given to the pharmacology of any CNS-active drug to be used with zoipidem. Any drug with CNS-depressant effects could potentially enhance the CNS-depressant effects of zoipidem.
Drugs that affect drug metabolism via cytochrome P450: A randomized, doubleblind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zoipidem (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUCo_m of zoipidem. There were no significant pharmacodynamic effects of zolpidem on subjective drowsiness, postural sway, or psychomotor performance.
A randomized, placebo-controlled, crossover interaction study in eight healthy female volunteers between 5 consecutive daily doses of rifampin (600 mg) and a single dose of zoipidem (20 mg} given 17 hours after the last dose of rifampin showed significant reductions of the AUC (-73%), C^ (-58%), and T w (-36%) of zoipidem together with significant reductions in the pharmacodynamic effects of zoipidem. Other drugs: A study involving cimetidine/zolpidem and ranitidine/zolpidem combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zoipidem. Zoipidem had no effect on digoxin kinetics and did not affect prothrombin time when given with warfarin in normal subjects. Zoipidem's sedative/hypnotic effect was reversed by flumazenil; however, no significant alterations in zoipidem pharmacokinetics were found. Drug/Laboratory test interactions: Zoipidem is not known to interfere with commonly employed clinical laboratory tests. In addition, clinical data indicate that zoipidem does not cross-react with benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screens. Carcinogenesis, mutagenssis, impairment of fertility Cardnogenesis: Zoipidem was administered to rats and mice for 2 years at dietary dosages of 4,18, and 80 mg/kg/day. In mice, these doses are 26 to 520 times or 2 to 35 times the maximum 10-mg human dose on a mg/kg or mg/m 1 basis, respectively. In rats these doses are 43 to 876 times or 6 to 115 times the maximum 10-mg human dose on a mg/kg or mg/m : basis, respectively. No evidence of carcinogenic potential was observed in mice, Renal liposarcomas were seen in 4/100 rats (3 males, 1 female) receiving 80 mg/kg/day and a renal lipoma was observed in one male rat at the 18 mg/kg/day dose. Incidence rates of lipoma and liposarcoma for zoipidem were comparable to those seen in historical controls and the tumor findings are thought to be a spontaneous occurrence. Mutagenesis: Zoipidem did not have mutagenic activity in several tests including the Ames test, genotoxicity in mouse lymphoma cells in vitro, chromosomal aberrations in cultured human lymphocytes, unscheduled DNA synthesis in rat hepatocytes in vitro, and the micronucleus test in mice. Impairment of fertility: In a rat reproduction study, the high dose (100 mg base/kg) of zoipidem resulted in irregular estrus cycles and prolonged precoital intervals, but there was no effect on male or female fertility after daily oral doses of 4 to 100 mg base/kg or 5 to 130 times the recommended human dose in mg/nf. No effects on any other fertility parameters were noted. Pregnancy Teratogenic effects: Category B. Studies to assess the effects of zoipidem on human reproduction and development have not been conducted.
Teratology studies were conducted in rats and rabbits. In rats, adverse maternal and fetal effects occurred at 20 and 100 mg base/kg and included dose-related maternal lethargy and ataxia and a dose-related trend to incomplete ossification of fetal skull bones.
In rabbits, dose-related maternal sedation and decreased weight gain occurred at all doses tested. At the high dose, 16 mg base/kg, there was an increase in postimplantation fetal loss and underossification of sternebrae in This drug should be used during pregnancy only if clearly needed. Nonteratogenic effects: Studies to assess the effects on children whose mothers took zoipidem during pregnancy have not been conducted. However, children born of mothers taking sedative/hypnotic drugs may be at some risk for withdrawal symptoms from the drug during the postnatal period. In addition, neonatal flaccidity has been reported in infants born of mothers who received sedative/ hypnotic drugs during pregnancy.
Labor and delivery:
Ambien has no established use in labor and delivery. Nursing mothers: Studies in lactating mothers indicate that between 0.004 and 0.019% of the total administered dose is excreted into milk, but the effect of zoipidem on the infant is unknown.
The use of Ambien in nursing mothers is not recommended. Pedistric use: Safety and effectiveness in pediatrtc patients below the age of 18 have not been established.
Geriatric use:
A total of 154 patients in U.S. controlled clinical trials and 897 patients in non-U.S. clinical trials who received zoipidem were 260 years of age. For a pool of U.S. patients receiving zoipidem at doses of £10 mg or placebo, there were three adverse events occurring at an incidence of at least 3% for zoipidem and for which the zoipidem incidence was at least twice the placebo incidence (ie, they could be considered drug related).
Adverse Event Zoipidem Placebo
Dizziness Drowsiness Diarrhea 3% 5% 3% 0% 2% 1%
A total of 30/1,959 (1.5%) non-U.S. patients receiving zoipidem reported falls, including 28/30 (93%) who were 270 years of age. Of these 28 patients, 23 (82%) were receiving zolpidem doses >10 mg. A total of 24/1,959 (1.2%) non-U.S, patients receiving zoipidem reported confusion, including 18/24 (75%) who were a7Q years of age. Of these 18 patients, 14 (78%) were receiving zoipidem doses >10 mg. ADVERSE REACTIONS Associated with discontinuation of treatment: Approximately 4% of 1,701 patients who received zoipidem at all doses (1.25 to 90 mg) in U.S. premarketing clinical trials discontinued treatment because of an adverse clinical event. Events most commonly associated with discontinuation from U.S. trials were daytime drowsiness (0.5%), dizziness (0.4%), headache (0.5%), nausea (0.6%), and vomiting (0.5%).
Approximately 4% of 1,959 patients who received zoipidem at all doses (1 to 50 mg) in similar foreign trials discontinued treatment because of an adverse event. Events most commonly associated with discontinuation from these trials were daytime drowsiness (1.1%), dizziness/vartigo (0.8%), amnesia (0.5%), nausea (0.5%), headache (0.4%), and falls (0.4%).
Data from a clinical study in which selective serotonin reuptake inhibitor-(SSR1) treated patients were given zoipidem revealed that four of the seven discontinuations during double-blind treatment with zoipidem (n=95) were associated with impaired concentration, continuing or aggravated depression, and manic reaction; one patient treated with placebo (n=97) was discontinued after an attempted suicide.
Incidence in controlled clinical tnflls
Most commonly observed adverse events in controlled trials: During short-term treatment (up to 10 nights) with Ambien at doses up to 10 mg, the most commonly observed adverse events associated with the use of zoipidem and seen at statistically significant differences from placebo-treated patients were drowsiness (reported by 2% of zoipidem patients), dizziness (1%), and diarrhea (1%), During longer-term treatment (28 to 35 nights) with zoipidem at doses up to 10 mg, the most commonly observed adverse events associated with the use of zoipidem and seen at statistically significant differences from placebo-treated patients were dizziness (5%) and drugged feelings (3%).
Treatment-emergent adverse experiences in placebo-controlled clinical trials:
The following are treatment-emergent adverse events from U.S. placebo-controlled clinical trials. Data are limited to data from doses up to and including 10 mg. In short-term trials, events seen in zoipidem patients (n=685) at an incidence equal to 1% or greater compared to placebo (n=473) were: headache (7% vs 6% for placebo), drowsiness (2% vs 0%), dizziness (1% vs 0%), nausea (2% vs 3%), diarrhea (1% vs 0%), and myalgia (1% vs 2%). In long-term clinical trials, events seen in zoipidem patients (n=152) at an incidence of 1% or greater compared to placebo (n=161) were: dry mouth [3% vs 1% for placebo), allergy (4% vs 1%), back pain (3% vs 2%), influenza-like symptoms (2% vs 0%), chest pain (1% vs 0%), fatigue (1% vs 2%), palpitation (2% vs 0%), headache (19% vs 22%), drowsiness (8% vs 5%), dizziness (5% vs 1%), lethargy (3% vs 1%), drugged feeling (3% vs 0%), lightheadedness (2% vs 1%), depression (2% vs 1%), abnormal dreams (1% vs 0%), amnesia (1% vs 0%), anxiety (1% vs 1%), nervousness (1% vs 3%), sleep disorder (1% vs 0%), nausea (6% vs 6%), dyspepsia (5% vs 6%), diarrhea (3% vs 2%), abdominal pain (2% vs 2%), constipation (2% vs 1%), anorexia (1% vs 1%), vomiting (1% vs 1%), infection (1% vs 1%), myalgia (7% vs 7%), arthralgia (4% vs 4%), upper respiratory infection (5% vs 6%), sinusitis (4% vs 2%), pharyngitis (3% vs 1%), rhinitis (1% vs 3%), rash (2% vs 1%), and urinary tract infection (2% vs 2%). Doss relationship for adverse events: There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse events associated with zoipidem use, particularly for certain CNS and gastrointestinal adverse events.
Adverse events are further classified and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients. Frequent: abdominal pain, abnormal dreams, allergy, amnesia, anorexia, anxiety, arthralgia, asthenia, ataxia, back pain, chest pain, confusion, constipation, depression, diarrhea, diplopia, dizziness, drowsiness, drugged feeling, dry mouth, dyspepsia, euphoria, fatigue, headache, hiccup, infection, influenza-like symptoms, insomnia, lethargy, lightheadedness, myalgia, nausea, nervousness, palpitation, sleep disorder, vertigo, vision abnormal, vomiting. Infrequent: abnormal hepatic function, agitation, arthritis, bronchitis, cerebrovascular disorder, coughing, cystitis, decreased cognition, detached, difficulty concentrating, dysarthria, dysphagia, dyspnea, edema, emotional lability, eye irritation, eye pain, falling, fever, flatulence, gastroenteritis, hallucination, hyperglycemia, hypertension, hypoesthesia, illusion, increased SGPT, increased sweating, leg cramps, malaise, menstrual disorder, migraine, pallor, paresthesia, postural hypotension, pruritus, scleritis, sleeping (after daytime dosing), speech disorder, stupor, syncope, tachycardia, taste perversion, thirst, tinnitus, trauma, tremor, urinary incontinence, vaginitis.
Rare: abdominal body sensation, abnormal accommodation, abnormal gait, abnormal thinking, abscess, acne, acute renal failure, aggressive reaction, allergic reaction, allergy aggravated, altered saliva, anaphylactic shock, anemia, angina pectoris, apathy, appetite increased, arrhythmia, arteritis, arthrosis, bilirubinemia, breast fibroadenosis, breast neoplasm, breast pain, bronchospasm, bullous eruption, circulatory failure, conjunctivitis, corneal ulceration, decreased libido, delusion, dementia, depersonalization, dermatitis, dysphasia, dysuria, enteritis, epistaxis, eructation, esophagospasm, extrasystoles, face edema, feeling strange, flushing, furunculosis, gastritis, glaucoma, gout, hemorrhoids, herpes simplex, herpes zoster, hot flashes, hypercholesteremia, hyperhemoglobinemia, hyperlipidemia, hypertension aggravated, hypokinesia, hypotension, hypotonia, hypoxia, hysteria, impotence, increased alkaline phosphatase, increased BUN, increased ESR, increased saliva, increased SGOT, injection-site inflammation, intestinal obstruction, intoxicated feeling, lacrimation abnormal, laryngitis, leukopenia, lymphadenopathy, macrocytic anemia, manic reaction, micturition frequency, muscle weakness, myocardial infarction, neuralgia, neuritis, neuropathy, neurosis, nocturia, otitis externa, otitis media, pain, panic attacks, paresis, parosmia, periorbital edema, personality disorder, phlebitis, photopsia, photosensitivity reaction, pneumonia, polyuria, pulmonary edema, pulmonary embolism, purpura, pyelonephritis, rectal hemorrhage, renal pain, restless legs, rigors, sciatica, somnambulism, suicide attempts, tendinitis, tenesmus, tetany, thrombosis, tolerance increased, tooth caries, urinary retention, urticaria, varicose veins, ventricular tachycardia, weight decrease, yawning.
DRUG ABUSE AND DEPENDENCE Controlled substance: Schedule IV. Abuse and dependence: Studies of abuse potential in former drug abusers found that the effects of single doses of zoipidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while zoipidem tartrate 10 mg was difficult to distinguish from placebo.
Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, and convulsions. The U.S. clinical trial experience from zoipidem does not reveal any clear evidence for withdrawal syndrome. Nevertheless, the following adverse events included in DSM-III-R criteria for uncomplicated sedative/hypnotic withdrawal were reported at an incidence of £1% during U.S. clinical trials following placebo substitution occurring within 48 hours following last zoipidem treatment: fatigue, nausea, flushing, lightheadedness, uncontrolled crying, emesis, stomach cramps, panic attack, nervousness, and abdominal discomfort. Rare post-marketing reports of abuse, dependence and withdrawal have been received. Individuals with a history of addiction to, or abuse of, drugs or alcohol are at increased risk of habitation and dependence; they should be under careful surveillance when receiving any hypnotic. OVERDOSAGE Signs and symptoms: In European postmarketing reports of overdose with zoipidem alone, impairment of consciousness has ranged from somnolence to light coma, with one case each of cardiovascular and respiratory compromise. Individuals have fully recovered from zoipidem tartrate overdoses up to 400 mg (40 times the maximum recommended dose). Overdose cases involving multiple CNS-depressant agents, including zoipidem, have resulted in more severe symptomatology, including fatal outcomes. Recommended treatment: General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Flumazenil may be useful. Respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Sedating drugs should be withheld following zoipidem overdosage. Zoipidem is not dialyzable.
The possibility of multiple drug ingestion should be considered. Rxonly sanoFi~synthelabo Distributed by: Sanofi-Synthelabo Inc. New York, NY 10016
